Skip to content

Clinical trials

Observational Precursor Cell Lymphoblastic Leukemia-Lymphoma trials in France

Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.

Filters: Condition: Precursor Cell Lymphoblastic Leukemia-Lymphoma Phase: Observational Country / region: France Clear all

34 trials match Source: ClinicalTrials.gov registrations

Trials started per year

By phase, 2000 to 2026.

Trials started per year
CategoryTrials
20001
20031
20051
20091
20111
20121
20132
20161
20171
20182
20204
20216
20225
20232
20243
20262

Status

Trials by registry status. Select a bar to filter.

Trials by status
CategoryTrials
Completed16
Unknown status10
Recruiting6
Terminated1
Withdrawn1

Top lead sponsors

A sponsor with a page on Pharma Observatory links to it.

Top lead sponsors
CategoryTrials
Assistance Publique - Hôpitaux de Paris4
Hospices Civils de Lyon4
Versailles Hospital3
Amgen2
European Organisation for Research and Treatment of Cancer - EORTC2
Novartis Pharmaceuticals2
University Hospital, Montpellier2
Bicetre Hospital1
Central Hospital, Nancy, France1
Centre Hospitalier Universitaire de Nīmes1

Top conditions

MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.

Top conditions
CategoryTrials
Precursor Cell Lymphoblastic Leukemia-Lymphoma34
Leukemia, Myeloid, Acute4
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma3
Breast Neoplasms2
Colonic Neoplasms2
Infections2
Leukemia2
Leukemia, Lymphocytic, Chronic, B-Cell2
Leukemia, Myelogenous, Chronic, BCR-ABL Positive2
Lymphoma2

Trials

Showing 1 to 25 of 34. Each trial links to its page on Pharma Observatory.

Recently changed trials

Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.

No changes to these trials in the last 7 days.

Go deeper on Pharma Observatory

Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.